Moderna finalizes plan for long-term strategic partnership with the government of canada

Onshore manufacturing facility is expected to be based in quebec and produce up to 100 million mrna respiratory vaccine doses annually the ten-year strategic partnership is expected to provide canadians with rapid response capabilities to ensure future pandemic readiness cambridge, ma / accesswire / april 29, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced its plan to build a state-of-the-art mrna vaccine manufacturing facility in quebec that will support a long-term strategic partnership with the government of canada to enhance pandemic preparedness. this milestone follows the signing of a memorandum of understanding between moderna and the government of canada in august 2021.
MRNA Ratings Summary
MRNA Quant Ranking